Herpes zoster oticus

Other names:Ramsay Hunt syndrome type 2 Hunt's syndrome (formerly); Hunt syndrome (formerly);

Summary

Herpes zoster oticus is a common complication of shingles, an infection caused by the varicella-zoster virus (which is the virus that also causes chickenpox).

Evolution of herpes zoster

Shingles

Shingles occurs in people who have had chickenpox and in whom the varicella-zoster virus becomes active again. Herpes zoster oticus is caused by the spread of the virus to facial nerves and can cause intense ear pain; a rash around the ear, mouth, face, neck, and scalp; and paralysis of the face. Other symptoms may include hearing loss, vertigo (feeling that the room is spinning), tinnitus (hearing abnormal sounds), nausea, vomiting, loss of taste in the tongue, and dry mouth and eyes. Some cases of herpes zoster oticus do not require treatment, but when treatment is needed, pain medications, antiviral drugs or corticosteroids may be prescribed. Vertigo is sometimes treated with medication as well. The prognosis of herpes zoster oticus is typically good, but in some cases hearing loss or facial paralysis may be permanent.

Error creating thumbnail:

Man with herpes zoster

Treatment

Prompt treatment of herpes zoster oticus is important for symptom relief and long-term outlook. Treatment typically includes anti-inflammatory drugs called steroids, which may reduce the inflammation of the nerves and help to ease the pain. Antiviral medications, such as acyclovir or valacyclovir, are often prescribed, although whether antiviral medications are beneficial for treating this condition has not been confirmed. Strong pain medications may be prescribed if the pain continues. An eye patch may be recommended to prevent injury to the cornea (corneal abrasion) and damage to the eye if it does not close completely. Vertigo and dizziness may be treated with other medications.

FDA-Approved Treatments

The medication(s) listed below have been approved by the Food and Drug Administration (FDA) as orphan products for treatment of this condition. Learn more orphan products. Capsaicin (Brand name: Qutenza) - Manufactured by NeurogesX, Inc. FDA-approved indication: Management of neuropathic pain associated with postherpetic neuralgia

• From an alternative name: This is a redirect from a title that is another name or identity such as an alter ego, a nickname, or a synonym of the target, or of a name associated with the target.
  • This redirect leads to the title in accordance with the naming conventions for common names to aid searches and writing. It is not necessary to replace these redirected links with a piped link.
  • If this redirect is an incorrect name for the target, then {{R from incorrect name}} should be used instead.

External links

Classification	ICD-10: B02.2 (ILDS B02.270), G53.0 ICD-9-CM: 053.11 MeSH: D016697 DiseasesDB: 11176
External resources	MedlinePlus: 001647 eMedicine: neuro/420

• NINDS Herpes Zoster Oticus Information Page National Institute of Neurological Disorders and Stroke
• Vaccine at Centers for Disease Control and Prevention